UCB in-licenses epratuzumab

Immunomedics (IMMU) granted UCB (Euronext:UCB) an exclusive worldwide license to develop, market and sell epratuzumab ( IMMU-103) for autoimmune indications. The humanized MAb targeting CD22 is in Pha...